/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with …
$14.77
$0.57 (-3.72%)
EOD Sep 18, 2026
Negative free cash flow of -$96M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$287M
▲ +23.0% YoY
Op. Margin
—
ROIC
-59.24%
▲ +7.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$98M
▲ +12.7% YoY
Op. Cash Flow (TTM)
-$98M
▲ +12.8% YoY
Net Debt
-$224M
Net Cash Position
Cash & Equiv.
$269M
Continue Research
SourceComputed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.